Invion Ltd (ASX: IVX) Share Price and News

Ms Leydin is now the Executive Vice President of Global Soultions, Southeast Asia at Vistra. Vistra is a provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Melanie has over 20 years of experience holding Board positions including Company Secretary and CFO of ASX listed entities. Melanie has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganization of Companies, initial public offerings, secondary raisings and shareholder relations.

Mr Chew has over 25 years of experience in healthcare biotech, investing and transforming business operations. He is also Co-Founder of Chronic Airway Therapeutics; a clinical stage firm focused on the treatment of respiratory diseases and Managing Partner at Polar Ventures. Thian is also an Advisory Board Member at Stanford Medicine's Center for Asian Health Research and Education (CARE). Prior to this, Thian was an Executive Director at Goldman Sachs (New York, Hong Kong), responsible for the firm's proprietary investments, and was a Consultant Project Manager at Morgan Stanley's Strategic Services Group (New York). He also held several positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large-scale operational restructurings, post-merger integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he led several business re-engineering initiatives, and performed financial and information technology audit, risk and assurance engagements across multiple industries. He is also Visiting Professor at UCL Global Business School for Health.

Mr Yamashita is an experienced corporate consultant and investment professional, with over 40 years of experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a private global hedge fund and private equity investment practice headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC. He is a Member of the Risk Committee.

Mr Field brings more than 30 years of experience in the global biopharmaceutical industry, across commercialisation, investment and strategic partnering of new drug candidates and therapeutic programs. Mr Field is currently a NED at 60 Degrees Pharmaceuticals the Executive Chair of Wintermute Biomedical Inc. and Head of Business Development at Alsonex Pty Ltd. He previously held positions at Neurizon Therapeutics Ltd., Horizon 3 Healthcare Fund and other biotech companies and organisations.